Scholarlink

<p>The current study outlines a consistent and reproducible protocol for the routine clinical dose preparation of [<sup>68</sup>Ga]Ga-Pentixafor using the Eckert and Ziegler ‘Modular-Lab Standard’ non-cassette based automated module, that can be effectively used in the hospital radiopharmacy unit of a high volume nuclear medicine centre. The pre-clinical studies (including in-vitro cell line studies, in-vivo PET/CT imaging and pre-clinical dosimetry) were conducted to show the promising potential of the product for clinical use in targeting CXCR4 tumor overexpression. PET/CT image of SCID mouse bearing lymphoma xenograft tumor, at 2&#xa0;h post-injection, clearly delineated the tumor. The pre-clinical dosimetry results show the suitability of the product for clinical use in patients. [<sup>68</sup>Ga]Ga-Pentixafor when administered to patients with primary aldosteronism exhibited distinct uptake in the adrenal nodules. The clinical PET/CT scan of the patients demonstrated the potential use of CXCR4 targeted imaging as a promising surgical decision-making tool for patients with primary aldosteronism.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

On the automated radiosynthesis of pharmaceutical grade [68Ga]Ga-Pentixafor, its pre-clinical evaluation, clinical application and radiation dosimetry aspects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月22日

查看全文
  • Sreeja Raj Menon,
  • Sudeep Sahu,
  • Arpit Mitra,
  • Avik Chakraborty,
  • Gaurav Malhotra,
  • Kamaldeep,
  • Megha Tawate,
  • Sangita Lad,
  • Sutapa Rakshit,
  • Trupti Upadhye,
  • Mukti Kanta Ray,
  • Sharmila Banerjee

摘要

The current study outlines a consistent and reproducible protocol for the routine clinical dose preparation of [68Ga]Ga-Pentixafor using the Eckert and Ziegler ‘Modular-Lab Standard’ non-cassette based automated module, that can be effectively used in the hospital radiopharmacy unit of a high volume nuclear medicine centre. The pre-clinical studies (including in-vitro cell line studies, in-vivo PET/CT imaging and pre-clinical dosimetry) were conducted to show the promising potential of the product for clinical use in targeting CXCR4 tumor overexpression. PET/CT image of SCID mouse bearing lymphoma xenograft tumor, at 2 h post-injection, clearly delineated the tumor. The pre-clinical dosimetry results show the suitability of the product for clinical use in patients. [68Ga]Ga-Pentixafor when administered to patients with primary aldosteronism exhibited distinct uptake in the adrenal nodules. The clinical PET/CT scan of the patients demonstrated the potential use of CXCR4 targeted imaging as a promising surgical decision-making tool for patients with primary aldosteronism.